Global Cervical Cancer Therapeutics Market 2019-2023

子宮頸がん治療法の世界市場2019-2023

◆タイトル:Global Cervical Cancer Therapeutics Market 2019-2023
◆商品コード:IRTNTR31252
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年5月16日
◆ページ数:124
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:Health Care
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、子宮頸がん治療法の世界市場について調査・分析し、市場概要、市場環境、子宮頸がん治療法市場規模、タイプ別(薬、ワクチン)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・子宮頸がん治療法の世界市場概要
・子宮頸がん治療法の世界市場環境
・子宮頸がん治療法の世界市場動向
・子宮頸がん治療法の世界市場規模
・子宮頸がん治療法の世界市場:業界構造分析
・子宮頸がん治療法の世界市場:タイプ別(薬、ワクチン)
・子宮頸がん治療法の世界市場:地域別市場規模・分析
・子宮頸がん治療法の北米市場規模・予測
・子宮頸がん治療法のヨーロッパ・中東・アフリカ市場規模・予測
・子宮頸がん治療法のアジア太平洋市場規模・予測
・子宮頸がん治療法の主要国分析
・子宮頸がん治療法の世界市場:意思決定フレームワーク
・子宮頸がん治療法の世界市場:成長要因、課題
・子宮頸がん治療法の世界市場:競争環境
・子宮頸がん治療法の世界市場:関連企業情報(ベンダー分析)

About this market

The advancements in diagnostics are one of the key factors expected to trigger the cervical cancer therapeutics market during the forecast period. Many medical devices companies are focusing on developing a revolutionary modular device for cervical cancer screening and diagnosis. This device has a dedicated computer with proprietary software, which helps in the accurate diagnosis of cancer. Therefore, such advances in diagnostic techniques of cervical cancers will not only help in identifying the correct stage of the carcinoma but also aid the oncologists in providing the right treatment to patients. Technavio’s analysts have predicted that the cervical cancer therapeutics market will register a CAGR of nearly 7% by 2023.

Market Overview

The growing popularity of targeted therapies

The growing R&D in this space and the positive clinical trials of late-stage molecules further support the growth prospects of the global cervical cancer treatment market during the forecast period.

Limited access to treatment

The lack of awareness and access to appropriate providers have been limiting the diagnosis and treatment of various cancers including cervical cancer.

For the detailed list of factors that will drive and challenge the growth of the cervical cancer therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【資料の目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY TYPE

Market segmentation by type

Comparison by type

Drugs – Market size and forecast 2018-2023

Vaccines – Market size and forecast 2018-2023

Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 14: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bristol-Myers Squibb Co.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Merck & Co. Inc.

Novartis AG

PART 15: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

Exhibit 01: Global oncology therapeutics market

Exhibit 02: Segments of global oncology therapeutics market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Some of the late-stage molecules for cervical cancer

Exhibit 18: Type – Market share 2018-2023 (%)

Exhibit 19: Comparison by type

Exhibit 20: Drugs – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Drugs – Year-over-year growth 2019-2023 (%)

Exhibit 22: Vaccines – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Vaccines – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by type

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 36: Top 3 countries in Asia

Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in ROW

Exhibit 40: Key leading countries

Exhibit 41: Market opportunity

Exhibit 42: Impact of drivers and challenges

Exhibit 43: Vendor landscape

Exhibit 44: Landscape disruption

Exhibit 45: Vendors covered

Exhibit 46: Vendor classification

Exhibit 47: Market positioning of vendors

Exhibit 48: Bristol-Myers Squibb Co. – Vendor overview

Exhibit 49: Bristol-Myers Squibb Co. – Business segments

Exhibit 50: Bristol-Myers Squibb Co. – Organizational developments

Exhibit 51: Bristol-Myers Squibb Co. – Geographic focus

Exhibit 52: Bristol-Myers Squibb Co. – Key offerings

Exhibit 53: Bristol-Myers Squibb Co. – Key customers

Exhibit 54: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 55: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 56: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 57: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 58: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 59: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 60: F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 61: GlaxoSmithKline Plc – Vendor overview

Exhibit 62: GlaxoSmithKline Plc – Business segments

Exhibit 63: GlaxoSmithKline Plc – Organizational developments

Exhibit 64: GlaxoSmithKline Plc – Geographic focus

Exhibit 65: GlaxoSmithKline Plc – Segment focus

Exhibit 66: GlaxoSmithKline Plc – Key offerings

Exhibit 67: GlaxoSmithKline Plc – Key customers

Exhibit 68: Merck & Co. Inc. – Vendor overview

Exhibit 69: Merck & Co. Inc. – Business segments

Exhibit 70: Merck & Co. Inc. – Organizational developments

Exhibit 71: Merck & Co. Inc. – Geographic focus

Exhibit 72: Merck & Co. Inc. – Segment focus

Exhibit 73: Merck & Co. Inc. – Key offerings

Exhibit 74: Merck & Co. Inc. – Key customers

Exhibit 75: Novartis AG – Vendor overview

Exhibit 76: Novartis AG – Business segments

Exhibit 77: Novartis AG – Organizational developments

Exhibit 78: Novartis AG – Geographic focus

Exhibit 79: Novartis AG – Segment focus

Exhibit 80: Novartis AG – Key offerings

Exhibit 81: Novartis AG – Key customers

Exhibit 82: Validation techniques employed for market sizing

Exhibit 83: Definition of market positioning of vendors



【掲載企業】

Bristol-Myers Squibb Co.、F. Hoffmann-La Roche Ltd.、GlaxoSmithKline Plc、Merck & Co. Inc.、Novartis AG

★調査レポート[子宮頸がん治療法の世界市場2019-2023] (Global Cervical Cancer Therapeutics Market 2019-2023 / IRTNTR31252)販売に関する免責事項
[子宮頸がん治療法の世界市場2019-2023] (Global Cervical Cancer Therapeutics Market 2019-2023 / IRTNTR31252)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆